Cartesian Therapeutics (RNAC) Net Margin: 2015-2025
Historic Net Margin for Cartesian Therapeutics (RNAC) over the last 11 years, with Sep 2025 value amounting to -4,318.14%.
- Cartesian Therapeutics' Net Margin fell 44166.00% to -4,318.14% in Q3 2025 from the same period last year, while for Sep 2025 it was -7,218.24%, marking a year-over-year decrease of 664154.00%. This contributed to the annual value of -198.97% for FY2024, which is 64594.00% up from last year.
- As of Q3 2025, Cartesian Therapeutics' Net Margin stood at -4,318.14%, which was up 14.68% from -5,061.07% recorded in Q2 2025.
- In the past 5 years, Cartesian Therapeutics' Net Margin registered a high of 3,198.55% during Q4 2024, and its lowest value of -5,061.07% during Q2 2025.
- Over the past 3 years, Cartesian Therapeutics' median Net Margin value was -412.71% (recorded in 2023), while the average stood at -1,405.44%.
- Its Net Margin has fluctuated over the past 5 years, first crashed by 807,882bps in 2021, then spiked by 557,767bps in 2024.
- Quarterly analysis of 5 years shows Cartesian Therapeutics' Net Margin stood at 40.88% in 2021, then slumped by 579bps to 35.09% in 2022, then slumped by 241,421bps to -2,379.12% in 2023, then soared by 557,767bps to 3,198.55% in 2024, then tumbled by 44,166bps to -4,318.14% in 2025.
- Its Net Margin was -4,318.14% in Q3 2025, compared to -5,061.07% in Q2 2025 and -1,806.73% in Q1 2025.